tradingkey.logo

Fortrea Holdings Inc

FTRE
View Detailed Chart

10.650USD

+0.340+3.30%
Close 09/18, 16:00ETQuotes delayed by 15 min
967.02MMarket Cap
LossP/E TTM

Fortrea Holdings Inc

10.650

+0.340+3.30%
Intraday
1m
30m
1h
D
W
M
D

Today

+3.30%

5 Days

+4.11%

1 Month

+34.47%

6 Months

+10.48%

Year to Date

-42.90%

1 Year

-53.66%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-17

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
55 / 507
Overall Ranking
159 / 4723
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 11 analysts
Hold
Current Rating
7.650
Target Price
-23.96%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
Industry Leader
The company's revenue leads the industry, with the latest annual revenue totaling USD 2.70B.
Fairly Valued
The company’s latest PE is -0.91, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 91.16M shares, decreasing 19.72% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 8.51M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
Ticker SymbolFTRE
CompanyFortrea Holdings Inc
CEOMr. Anshul Thakrala
Websitehttps://www.fortrea.com/
KeyAI